Chin, Kazuo
Tachikawa, Ryo
Funding for this research was provided by:
Japanese Ministry of Education, Culture, Sports, Science and Technology
Intractable Respiratory Diseases and Pulmonary Hypertension Research Group
Welfare Science and Research Grants
Ministry of Health, Labor and Welfare of Japan
Japan Agency for Medical Research and Development (JP18ek0210096)
Article History
First Online: 25 April 2018
Compliance with Ethics Standards
:
: Kazuo Chin reports grants from The Japanese Ministry of Education, Culture, Sports, Science and Technology, grants from Respiratory Failure Research Group, the Ministry of Health, Labor and Welfare, Japan, grants from AMED, grants from The Ministry of Health, Labor and Welfare, Japan, grants from The Intractable Respiratory Diseases and Pulmonary Hypertension Research Group, the Ministry of Health, Labor and Welfare, Japan, during the conduct of the study; grants and personal fees from Philips Respironics, grants and personal fees from Teijin Pharma, grants and personal fees from Fukuda Denshi, grants and personal fees from Fukuda Lifetec Keiji, personal fees from KYORIN Pharmaceutical Co., Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from GlaxoSmithKline, personal fees from MSD, grants and personal fees from Resmed, personal fees from Eisai Co., Ltd., outside the submitted work.Ryo Tachikawa reports personal fees from Philips Respironics and Teijin Pharma outside of the submitted work.
: This article does not contain any studies with human or animal subjects performed by any of the authors.